查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2085506

基因改造T細胞市場：2026-2032年全球市場預測（依療法、細胞來源、研發階段、應用和最終用戶分類）

Engineered T Cells Market by Therapy Type, Cell Source, Phase, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，基因改造 T 細胞市場將成長至 419.9 億美元，複合年成長率為 8.06%。

主要市場統計數據
基準年 2025 244億美元
預計年份：2026年 262.9億美元
預測年份 2032 419.9億美元
複合年成長率 (%) 8.06%

基因改造的T細胞透過整合免疫學、基因工程、細胞處理和精準腫瘤學，為先進療法的開發開闢了新的前景。此領域包括嵌合體抗原受體T細胞療法、T細胞受體療法、腫瘤浸潤淋巴細胞療法、基因編輯T細胞以及旨在提高療效、持久性、安全性和擴充性的新型同種異體細胞療法平台。

商業性和臨床發展勢頭強勁，這得益於其在骨髓惡性腫瘤領域已獲批准的療法、在固體癌瘤領域不斷拓展的臨床試驗活動，以及對生產自動化、病毒和非病毒基因轉移和分析品管的持續投入。對於產業領導者而言，基因修飾T細胞正從腫瘤專科領域的特定應用發展成為一個具有戰略意義的生物製藥平台，其應用範圍涵蓋癌症治療、自體免疫疾病、移植醫學和罕見免疫疾病等領域。

基因修飾T細胞的轉化性變化

基因修飾T細胞領域正從第一代自體CAR-T療法轉型為更廣泛、更產業化的治療模式。關鍵轉變包括：治療標靶從CD19和BCMA擴展到多抗原標標靶化、裝甲T細胞、邏輯門結構以及針對HLA分子呈現的細胞內腫瘤抗原的TCR-T療法。

人工智慧的累積影響

人工智慧（AI）的應用不再局限於單一工作流程，其影響累積日益遍及基因修飾T細胞的整個價值鏈。在藥物研發領域，AI驅動的抗原選擇、新抗原預測、蛋白質設計和單細胞數據分析有助於標靶優先排序和受體構建最佳化。在轉化研究中，機器學習被用來分析腫瘤微環境訊號傳導、免疫表現型、細胞激素激素譜和抗藥性機制。

對關鍵區域的洞察

北美憑藉其完善的細胞和基因療法FDA核准流程、領先的學術癌症中心、先進的合約開發和生產能力以及高密度的臨床試驗，仍然是基因修飾T細胞領域的主導地區。歐洲受益於EMA對先進治療藥物的監管、國家醫保報銷談判以及強大的轉化醫學網路，同時歐盟也持續支持先進治療藥物在品質、可追溯性和藥物警戒方面的統一要求。

關鍵群體特定見解

在東協地區，新加坡的生物醫學中心、泰國和馬來西亞的醫院網路，以及該地區對兼顧可負擔性、轉診途徑和冷鏈物流的癌症治療創新需求，正在推動基因修飾T細胞療法的引入。海灣合作理事會（GCC）國家優先發展能夠支持先進腫瘤學服務、基因組醫學以及符合監管規定的治療中心、專家培訓和先進急診護理的夥伴關係。

主要國家的概況

美國憑藉FDA已通過核准的CAR-T和T細胞免疫療法產品、廣泛的產學研合作、專業的治療中心和先進的生產能力，在細胞療法領域發揮主導作用。加拿大透過癌症中心、醫療技術評估流程以及與國際標準的監管接軌來支持細胞療法的應用。同時，墨西哥正透過腫瘤學的現代化和跨國醫療合作來提升自身能力。巴西是拉丁美洲細胞療法發展領域最突出的國家，這得益於公共研究機構、醫院的創新以及沉重的癌症負擔。

為行業領導者提供的實用建議

產業領導者應優先考慮能夠證明標靶差異化、可生產性和持續療效（而不僅僅是緩解率）的臨床證據。相關策略應包括與監管機構的早期合作、可擴展的品管系統、完善的可比性計劃，以及針對細胞激素釋放症候群、免疫效應細胞相關神經毒性症候群、插入突變風險和長期隨訪的綜合藥物安全性監測。

調查方法

本執行摘要基於檢驗的二手研究，參考了監管機構、臨床試驗註冊中心、同行評審的生物醫學文獻、醫療政策文件以及已通過核准的細胞和基因療法等公開資訊。引用的資訊來源包括美國食品藥物管理局 (FDA)、歐洲藥品管理局 (EMA)、各國監管機構、ClinicalTrials.gov、歐盟臨床試驗註冊中心、世界衛生組織 (WHO) 資源以及權威科學期刊。

結論

基因改造T細胞療法正從個人化、突破性的療法發展成更具擴充性、數據驅動且可全球部署的治療平台。最大的機會在於那些能夠結合已驗證的生物學機制、差異化的臨床療效、可重複的生產過程以及對保險公司至關重要的治療結果的療法。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 基因改造T細胞市場：依治療類型分類

  • CAR T
  • TCR T

第8章：基因改造T細胞市場：依細胞來源分類

  • 同種異體移植
  • 本土種植

第9章 基因改造T細胞市場：依階段分類

  • 第一階段
  • 第二階段
  • 第三階段
  • 臨床前階段

第10章：基因改造T細胞市場：依應用領域分類

  • 自體免疫疾病
    • 狼瘡
    • 類風濕性關節炎
  • 感染疾病
  • 腫瘤學
    • 急性淋巴性白血病
    • 非何傑金氏淋巴瘤
    • 固體癌
      • 膠質母細胞瘤
      • 肺癌

第11章 基因改造T細胞市場：依最終用戶分類

  • 醫院
  • 研究機構
  • 專科診所

第12章 基因改造T細胞市場：依地區分類

  • 亞太地區
  • 北美洲
  • 拉丁美洲
  • 歐洲
  • 中東
  • 非洲

第13章 基因改造T細胞市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 基因改造T細胞市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第16章：公司簡介

  • Adaptimmune Therapeutics plc
  • Adaptin Bio, Inc.
  • Allogene Therapeutics, Inc.
  • Amgen Inc.
  • Atara Biotherapeutics, Inc.
  • Autolus Therapeutics plc
  • bluebird bio, Inc.
  • Bristol-Myers Squibb Company
  • CARsgen Therapeutics Ltd.
  • Clasp Therapeutics, Inc.
  • CRISPR Therapeutics AG
  • Fate Therapeutics, Inc.
  • Gilead Sciences, Inc.
  • Immatics NV
  • Immunocore Limited
  • Janux Therapeutics
  • Legend Biotech Corporation
  • Lion TCR Pte Ltd.
  • Novartis AG
  • Oxford Biomedica plc
  • Pfizer Inc.
  • Sangamo Therapeutics, Inc.
  • Sorrento Therapeutics, Inc.
  • TCR2 Therapeutics Inc.
Product Code: MRR-4348D129FAA9

The Engineered T Cells Market is projected to grow by USD 41.99 billion at a CAGR of 8.06% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 24.40 billion
Estimated Year [2026] USD 26.29 billion
Forecast Year [2032] USD 41.99 billion
CAGR (%) 8.06%

Engineered T cells are redefining advanced therapy development by combining immunology, genetic engineering, cell processing, and precision oncology. The field includes chimeric antigen receptor T-cell therapy, T-cell receptor therapy, tumor-infiltrating lymphocyte approaches, gene-edited T cells, and emerging allogeneic cell therapy platforms designed to improve potency, persistence, safety, and scalability.

Commercial and clinical momentum is supported by verified regulatory approvals in hematologic malignancies, expanding clinical trial activity across solid tumors, and sustained investment in manufacturing automation, viral and non-viral gene delivery, and analytical quality control. For industry leaders, engineered T cells have moved beyond a specialized oncology niche into a strategic biopharmaceutical platform with implications for cancer care, autoimmune disease, transplant medicine, and rare immune disorders.

Transformative Shifts in Engineered T Cells

The engineered T cells landscape is shifting from first-generation autologous CAR-T programs toward broader, more industrialized therapeutic models. Key changes include the expansion from CD19- and BCMA-directed therapies into multi-antigen targeting, armored T cells, logic-gated constructs, and TCR-T therapies aimed at intracellular tumor antigens presented by HLA molecules.

Manufacturing is also transforming. Closed-system processing, automated cell expansion, improved cryopreservation, and decentralized manufacturing models are being adopted to reduce vein-to-vein time and improve consistency. At the same time, gene editing technologies are advancing allogeneic T-cell candidates by addressing rejection, graft-versus-host disease risk, and product uniformity, although long-term safety, durability, and immune compatibility remain central regulatory considerations.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is increasingly cumulative across the engineered T cells value chain rather than confined to one workflow. In discovery, AI-supported antigen selection, neoantigen prediction, protein design, and single-cell data interpretation help prioritize targets and optimize receptor constructs. In translational research, machine learning is used to analyze tumor microenvironment signals, immune phenotypes, cytokine profiles, and resistance mechanisms.

In development and manufacturing, AI-enabled process monitoring can support batch consistency, deviation detection, potency assay interpretation, and predictive quality analytics. Clinical operations benefit from patient stratification, toxicity risk modeling, and real-world evidence analysis. These applications remain dependent on validated datasets, explainable models, regulatory-grade documentation, and human scientific oversight, making AI an accelerator of evidence generation rather than a substitute for clinical proof.

Key Regional Insights

North America remains a leading region for engineered T cells due to established FDA pathways for cell and gene therapies, major academic cancer centers, advanced contract development and manufacturing capacity, and high clinical trial density. Europe benefits from EMA advanced therapy medicinal product regulation, national reimbursement negotiations, and strong translational networks, while the European Union continues to support harmonized quality, traceability, and pharmacovigilance expectations for advanced therapy medicinal products.

Asia-Pacific is gaining scale through China's large clinical trial base, Japan's regenerative medicine framework, South Korea's biomanufacturing strengths, India's cost-sensitive innovation, and Australia's early-phase clinical research infrastructure. Latin America, led by Brazil and Mexico, is building access through oncology centers, public research initiatives, and regulatory modernization, but affordability and manufacturing infrastructure remain constraints. The Middle East, particularly GCC markets, is investing in precision medicine and tertiary care capacity, while Africa's opportunity depends on oncology infrastructure, cold-chain reliability, workforce development, and equitable access programs.

Key Group Insights

Within ASEAN, engineered T cells adoption is shaped by Singapore's biomedical hub, Thailand and Malaysia's hospital networks, and regional demand for cancer innovation balanced against affordability, referral pathways, and cryogenic logistics. The GCC is prioritizing advanced oncology services, genomic medicine, and partnerships that support compliant treatment centers, specialist training, and high-acuity care delivery.

The European Union provides one of the most structured regulatory environments for advanced therapy medicinal products, with emphasis on quality, traceability, pharmacovigilance, and post-authorization safety monitoring. BRICS countries collectively represent a major development frontier because China, India, Brazil, Russia, and South Africa combine large patient populations with expanding biotechnology capabilities and uneven access infrastructure. G7 countries anchor much of the innovation, reimbursement evidence, and manufacturing standard setting, while NATO-aligned countries benefit from resilient supply-chain coordination, advanced biomedical infrastructure, and cross-border clinical research collaboration.

Key Country Insights

The United States leads through FDA-approved CAR-T and T-cell immunotherapy products, extensive academic-industry collaboration, specialized treatment centers, and advanced manufacturing capacity. Canada supports adoption through cancer centers, health technology assessment processes, and regulatory alignment with international standards, while Mexico is developing capabilities through oncology modernization and cross-border healthcare linkages. Brazil is the most visible Latin American country for cell therapy development, supported by public research institutions, hospital-based innovation, and a large oncology burden.

In Europe, the United Kingdom has strong clinical translation through national health system infrastructure, cell therapy manufacturing networks, and academic centers; Germany, France, Italy, and Spain combine high oncology demand with advanced hospital systems, active clinical research, and reimbursement scrutiny. Russia maintains scientific expertise but faces access and supply-chain constraints. China has one of the world's most active engineered T-cell clinical pipelines; India is advancing lower-cost CAR-T innovation and domestic manufacturing; Japan has a defined regenerative medicine pathway; Australia supports early-phase trials and translational oncology research; and South Korea combines biomanufacturing strength with precision medicine investment.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize target differentiation, manufacturability, and clinical evidence that demonstrates durable benefit beyond response rate alone. Strategies should include early engagement with regulators, scalable quality systems, robust comparability plans, and integrated pharmacovigilance for cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, insertional risk, and long-term follow-up.

Commercial success will depend on shortening vein-to-vein time, strengthening referral networks, improving patient identification, and building value-based evidence for payers. Organizations should invest in AI-enabled analytics only when datasets are validated, auditable, and clinically interpretable. Partnerships with hospitals, contract manufacturers, academic centers, and regional health authorities can accelerate access while reducing operational risk in complex cell therapy ecosystems.

Research Methodology

This executive summary is based on verified secondary research from regulatory agencies, clinical trial registries, peer-reviewed biomedical literature, healthcare policy documents, and publicly available evidence on approved cell and gene therapies. Sources considered include FDA, EMA, national regulatory authorities, ClinicalTrials.gov, EU Clinical Trials Register, WHO resources, and established scientific journals.

The analysis triangulates therapeutic approvals, trial activity, manufacturing trends, regional infrastructure, reimbursement dynamics, and technology adoption. Qualitative assessment was applied to market drivers, barriers, regional readiness, and competitive positioning. No unverified market-size figures, market share estimates, or speculative forecasts are used; insights are framed around documented regulatory, clinical, operational, and technology signals.

Conclusion

Engineered T cells are advancing from individualized breakthrough therapies toward more scalable, data-driven, and globally distributed treatment platforms. The strongest opportunities are linked to therapies that combine validated biology, differentiated clinical benefit, reproducible manufacturing, and payer-relevant outcomes.

As CAR-T, TCR-T, TIL, and gene-edited allogeneic platforms evolve, the field will reward organizations that integrate scientific rigor with operational excellence. Stakeholders that align discovery, manufacturing, regulatory strategy, AI-enabled analytics, and access planning will be best positioned to lead the next phase of engineered T-cell therapy.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Engineered T Cells Market, by Therapy Type

  • 7.1. CAR T
  • 7.2. TCR T

8. Engineered T Cells Market, by Cell Source

  • 8.1. Allogeneic
  • 8.2. Autologous

9. Engineered T Cells Market, by Phase

  • 9.1. Phase I
  • 9.2. Phase Ii
  • 9.3. Phase Iii
  • 9.4. Preclinical

10. Engineered T Cells Market, by Application

  • 10.1. Autoimmune Diseases
    • 10.1.1. Lupus
    • 10.1.2. Rheumatoid Arthritis
  • 10.2. Infectious Diseases
  • 10.3. Oncology
    • 10.3.1. Acute Lymphoblastic Leukemia
    • 10.3.2. Non Hodgkin Lymphoma
    • 10.3.3. Solid Tumor
      • 10.3.3.1. Glioblastoma
      • 10.3.3.2. Lung Cancer

11. Engineered T Cells Market, by End User

  • 11.1. Hospital
  • 11.2. Research Institutes
  • 11.3. Specialty Clinics

12. Engineered T Cells Market, by Region

  • 12.1. Asia-Pacific
  • 12.2. North America
  • 12.3. Latin America
  • 12.4. Europe
  • 12.5. Middle East
  • 12.6. Africa

13. Engineered T Cells Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Engineered T Cells Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Concentration Analysis, 2025
    • 15.1.1. Concentration Ratio (CR)
    • 15.1.2. Herfindahl Hirschman Index (HHI)
  • 15.2. Recent Developments & Impact Analysis, 2025
  • 15.3. Product Portfolio Analysis, 2025
  • 15.4. Benchmarking Analysis, 2025

16. Company Profiles

  • 16.1. Adaptimmune Therapeutics plc
  • 16.2. Adaptin Bio, Inc.
  • 16.3. Allogene Therapeutics, Inc.
  • 16.4. Amgen Inc.
  • 16.5. Atara Biotherapeutics, Inc.
  • 16.6. Autolus Therapeutics plc
  • 16.7. bluebird bio, Inc.
  • 16.8. Bristol-Myers Squibb Company
  • 16.9. CARsgen Therapeutics Ltd.
  • 16.10. Clasp Therapeutics, Inc.
  • 16.11. CRISPR Therapeutics AG
  • 16.12. Fate Therapeutics, Inc.
  • 16.13. Gilead Sciences, Inc.
  • 16.14. Immatics N.V.
  • 16.15. Immunocore Limited
  • 16.16. Janux Therapeutics
  • 16.17. Legend Biotech Corporation
  • 16.18. Lion TCR Pte Ltd.
  • 16.19. Novartis AG
  • 16.20. Oxford Biomedica plc
  • 16.21. Pfizer Inc.
  • 16.22. Sangamo Therapeutics, Inc.
  • 16.23. Sorrento Therapeutics, Inc.
  • 16.24. TCR2 Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ENGINEERED T CELLS MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL ENGINEERED T CELLS MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL ENGINEERED T CELLS MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL ENGINEERED T CELLS MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL ENGINEERED T CELLS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 7. GLOBAL ENGINEERED T CELLS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 8. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CAR T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CAR T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CAR T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TCR T MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TCR T MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TCR T MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ALLOGENEIC MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ALLOGENEIC MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ALLOGENEIC MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AUTOLOGOUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AUTOLOGOUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AUTOLOGOUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PHASE I MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PHASE I MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PHASE I MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PHASE II MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PHASE II MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PHASE II MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PHASE III MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PHASE III MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PHASE III MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PRECLINICAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PRECLINICAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PRECLINICAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL LUPUS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL LUPUS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL LUPUS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL RHEUMATOID ARTHRITIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL INFECTIOUS DISEASES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ONCOLOGY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ONCOLOGY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ONCOLOGY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON HODGKIN LYMPHOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL SOLID TUMOR MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL SOLID TUMOR MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL SOLID TUMOR MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL GLIOBLASTOMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL GLIOBLASTOMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL GLIOBLASTOMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL LUNG CANCER MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL LUNG CANCER MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL LUNG CANCER MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HOSPITAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HOSPITAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HOSPITAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL RESEARCH INSTITUTES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SPECIALTY CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 79. ASIA-PACIFIC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 97. LATIN AMERICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. GCC ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 136. GCC ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. GCC ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 139. GCC ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 171. NATO ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ENGINEERED T CELLS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 190. CANADA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 191. CANADA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CANADA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 193. CANADA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 194. CANADA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 195. CANADA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 196. CANADA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 197. CANADA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 198. CANADA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. MEXICO ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 200. MEXICO ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 201. MEXICO ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 202. MEXICO ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 203. MEXICO ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 204. MEXICO ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 205. MEXICO ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 206. MEXICO ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 207. MEXICO ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. BRAZIL ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 209. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 210. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 211. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 212. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 213. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 214. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 215. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 216. BRAZIL ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 219. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 220. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 221. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 222. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 223. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 224. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 225. UNITED KINGDOM ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 226. GERMANY ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 227. GERMANY ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 228. GERMANY ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 229. GERMANY ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 230. GERMANY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 231. GERMANY ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 232. GERMANY ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 233. GERMANY ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 234. GERMANY ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. FRANCE ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 236. FRANCE ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. FRANCE ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 238. FRANCE ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 239. FRANCE ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 240. FRANCE ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 241. FRANCE ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 242. FRANCE ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 243. FRANCE ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. RUSSIA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 245. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 246. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 247. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 248. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 249. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 250. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 251. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 252. RUSSIA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 253. ITALY ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 254. ITALY ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 255. ITALY ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 256. ITALY ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 257. ITALY ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 258. ITALY ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 259. ITALY ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 260. ITALY ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 261. ITALY ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 262. SPAIN ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. SPAIN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. SPAIN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 265. SPAIN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 266. SPAIN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 267. SPAIN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 268. SPAIN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 269. SPAIN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 270. SPAIN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 271. CHINA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 272. CHINA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 273. CHINA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 280. INDIA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 281. INDIA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 282. INDIA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 283. INDIA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 284. INDIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 285. INDIA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 286. INDIA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 287. INDIA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 288. INDIA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 289. JAPAN ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 290. JAPAN ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 291. JAPAN ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 292. JAPAN ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 293. JAPAN ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 294. JAPAN ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 295. JAPAN ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 296. JAPAN ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 297. JAPAN ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 298. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 299. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 300. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 301. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 302. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 304. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 305. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 306. AUSTRALIA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 307. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 308. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY CELL SOURCE, 2018-2032 (USD MILLION)
  • TABLE 310. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY PHASE, 2018-2032 (USD MILLION)
  • TABLE 311. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 312. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2032 (USD MILLION)
  • TABLE 313. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 314. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY SOLID TUMOR, 2018-2032 (USD MILLION)
  • TABLE 315. SOUTH KOREA ENGINEERED T CELLS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)